Hikma Pharmaceuticals (LON:HIK) Raised to Overweight at Morgan Stanley

Morgan Stanley upgraded shares of Hikma Pharmaceuticals (LON:HIK) to an overweight rating in a report released on Tuesday morning, Digital Look reports. Morgan Stanley currently has GBX 2,600 ($32.00) target price on the stock, up from their previous target price of GBX 2,200 ($27.07).

Other research analysts have also recently issued research reports about the company. Jefferies Financial Group increased their price objective on Hikma Pharmaceuticals from GBX 2,300 ($28.30) to GBX 2,390 ($29.41) and gave the stock a buy rating in a research report on Thursday, March 12th. Citigroup increased their price objective on Hikma Pharmaceuticals from GBX 2,150 ($26.46) to GBX 2,500 ($30.77) and gave the stock a buy rating in a research report on Friday, April 3rd. Goldman Sachs Group cut Hikma Pharmaceuticals to a neutral rating and raised their price target for the stock from GBX 2,200 ($27.07) to GBX 2,400 ($29.53) in a research report on Friday, April 24th. JPMorgan Chase & Co. upgraded Hikma Pharmaceuticals to an overweight rating and raised their price target for the stock from GBX 1,850 ($22.77) to GBX 2,400 ($29.53) in a research report on Thursday, April 2nd. Finally, Peel Hunt restated a buy rating on shares of Hikma Pharmaceuticals in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of GBX 2,410 ($29.66).

HIK stock opened at GBX 2,105 ($25.90) on Tuesday. The company has a debt-to-equity ratio of 32.18, a current ratio of 1.26 and a quick ratio of 0.82. The stock has a market capitalization of $4.94 billion and a price-to-earnings ratio of 10.71. The business’s fifty day moving average price is GBX 2,370.28 and its two-hundred day moving average price is GBX 2,124.88. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,596 ($19.64) and a fifty-two week high of GBX 2,670 ($32.86).

In related news, insider Mazen Darwazah sold 1,350,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of GBX 2,450 ($30.15), for a total value of £33,075,000 ($40,702,682.75).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

Recommended Story: Why Invest in Dividend Kings

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.